Recursion Pharmaceuticals (RXRX) News Today $5.45 +0.08 (+1.49%) Closing price 04:00 PM EasternExtended Trading$5.48 +0.03 (+0.55%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is Recursion Pharmaceuticals Up Today?Recursion Pharmaceuticals, Inc. (RXRX) shares have climbed on hopes that recent cost‐cutting measures and AI platform upgrades will boost efficiency and drive future growth, even as concerns linger over workforce reductions and trial readout risks. Next-Gen AI Boost: Unveiling enhancements to its AI-driven drug discovery platform sparked strong buying, with shares jumping over 30% on the news. Cost-Saving Strategy: Investors welcomed the company’s plan to streamline operations and extend cash runway, bidding up the stock by roughly 10% at one point. Trading Momentum: Heavy volume and intraday gains (up around 5–10%) reflect renewed investor interest behind these catalysts. Analyst & Media Coverage: Multiple “buy/hold” alerts, gap-up analyses and Benzinga/S&P MarketBeat write-ups have kept the name in focus. Short Interest: Borrowing levels remain near zero with virtually no days-to-cover, suggesting limited bearish positioning. Layoffs & Pipeline Cuts: The company announced a 20% workforce reduction alongside cuts to certain research programs, underscoring pressure to curb cash burn during a biotech downturn. Readout Uncertainty: Recent trial results were deemed disappointing and upcoming data releases carry execution risk, which may weigh on sentiment if outcomes fall short. Posted 3h agoAI Generated. May Contain Errors. RXRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?June 10 at 8:55 PM | benzinga.comRecursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts RiskyJune 10 at 8:55 PM | seekingalpha.comRecursion Pharma to reduce workforce by 20%June 10 at 8:55 PM | msn.comRecursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AIJune 10 at 8:55 PM | msn.comWhy Recursion Pharmaceuticals Was Bouncing Higher on TuesdayJune 10 at 6:03 PM | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.9% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.9% - Should You Buy?June 10 at 2:15 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - Should You Buy?June 10 at 11:57 AM | marketbeat.comRecursion to lay off 20% of workforce, narrows focus amid biotech downturnJune 10 at 6:14 AM | reuters.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?June 9 at 12:20 PM | marketbeat.comCalifornia State Teachers Retirement System Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)California State Teachers Retirement System lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 30.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 231,535 sharesJune 9 at 3:41 AM | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Soared On FridayJune 7 at 2:50 PM | insidermonkey.comRecursion Pharmaceuticals shares surge on AI model releaseJune 7 at 4:48 AM | investing.comJuly 25th Options Now Available For Recursion Pharmaceuticals (RXRX)June 7 at 4:48 AM | nasdaq.comMIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and AccuracyJune 6, 2025 | globenewswire.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.1% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.1% - Here's WhyJune 5, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Should You Buy?June 4, 2025 | marketbeat.comInvestors Buy High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock traders acquired 60,432 call options on the stock. This represents an increase of approximately 148% compared to the typical volume of 24,409 call options.June 4, 2025 | marketbeat.comSquarepoint Ops LLC Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Squarepoint Ops LLC bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 80,421 shares of the company's stock, valued at approximJune 4, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 7.3% - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 7.3% - Here's What HappenedJune 3, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Position Raised by Green Alpha Advisors LLCGreen Alpha Advisors LLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 166.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 178,873 shares of the company's stock after acqJune 2, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.60 Consensus PT from AnalystsJune 2, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.1% - Here's What HappenedJune 1, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.1% - Here's What HappenedRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.1% - Here's What HappenedMay 31, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $15.27 Million Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutiMay 31, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from AnalystsShares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been given an average recommendation of "Hold" by the six analysts that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and two have given a buy ratingMay 31, 2025 | marketbeat.comRecursion to Participate in Upcoming Investor ConferencesMay 30, 2025 | globenewswire.comWas Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?May 30, 2025 | insidermonkey.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.2% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.2% Higher - Time to Buy?May 29, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Still a Buy?May 29, 2025 | marketbeat.com70,802 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Man Group plcMan Group plc bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 70,802 shares of the compaMay 28, 2025 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsMay 26, 2025 | fool.comTwo Sigma Investments LP Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Two Sigma Investments LP grew its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 4.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,660,509 shares of the company's stock after purchasing an additional 63,211 shares dMay 26, 2025 | marketbeat.comDeutsche Bank AG Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Deutsche Bank AG lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 217,723 shares of the company's stock after acquiMay 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising SalesMay 24, 2025 | finance.yahoo.comThese Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio (RXRX)While institutional money managers have released their Q1 holdings, so has the heart and soul of the AI revolution, NVIDIA. See which six stocks NVIDIA owns.May 22, 2025 | marketbeat.comRafferty Asset Management LLC Cuts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Rafferty Asset Management LLC decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 11.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 595,472 shares of the company's stock after selling 80,319May 21, 2025 | marketbeat.comRaiffeisen Bank International AG Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Raiffeisen Bank International AG purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 150,000 shares of the company's stock, valued at approxiMay 19, 2025 | marketbeat.comLazard Asset Management LLC Has $3.76 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Lazard Asset Management LLC lowered its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 555,850 shares of the company's stock after selling 86,458 shares during the period. LMay 19, 2025 | marketbeat.comSoftbank Group CORP. Invests $99.15 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Softbank Group CORP. acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,667,491 shares of the company's stock, vMay 18, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Northern Trust CorpNorthern Trust Corp boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 18.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,394,511 shares of the company's stock after acquiring an additional 371,886 shares duMay 17, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams StallMay 15, 2025 | insidermonkey.comRecursion Pharmaceuticals: High-Risk Play Getting Riskier By The QuarterMay 14, 2025 | seekingalpha.comRecursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy NowMay 14, 2025 | msn.comLaurion Capital Management LP Invests $16.61 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Laurion Capital Management LP bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,457,189May 14, 2025 | marketbeat.comShould You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?May 12, 2025 | fool.com2 Top Artificial Intelligence (AI) Stocks to Buy Right NowMay 11, 2025 | fool.comLeerink Partnrs Has Bullish Estimate for RXRX Q2 EarningsRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Equities researchers at Leerink Partnrs lifted their Q2 2025 EPS estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now expects that theMay 10, 2025 | marketbeat.comRaymond James Financial Inc. Acquires New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Raymond James Financial Inc. purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 90,107 shares of the company's stock, valued atMay 10, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Plummeted 24% This WeekMay 9, 2025 | fool.com66,900 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Bayesian Capital Management LPBayesian Capital Management LP bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 66,900 shares of the company's stock, valuMay 9, 2025 | marketbeat.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Videos RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.690.68▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼1510▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Blueprint Medicines News Today Roivant Sciences News Today Revolution Medicines News Today BridgeBio Pharma News Today Elanco Animal Health News Today Verona Pharma News Today Legend Biotech News Today TG Therapeutics News Today Grifols News Today Lantheus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXRX Stock Free RXRX Stock Alerts